点击图片查看原图
Biotin cRNA 扩增与标记试剂盒
LipoD293™ 体外DNA转染试剂（免费试
![pGL4.26[luc2/minP/Hygro]载体](images/333/c1.jpg)
pGL4.26[luc2/minP/Hygro]载体
[VIP第1年] 指数:3
通过闵行区市场监督管理局认证 
IV型胶原蛋白/4型胶原
MicroVue CICP EIA*| 货号： | XY1399 |
| 供应商： | 信裕生物 |
| 数量： | 60 |
| 英文名： | pMIR-REPORT Luciferase |
| 保质期： | 三年 |
| 保存条件： | 常温 |
| 规格： | 5ug质粒 |
基本信息
| 质粒类型: | RNAi载体 |
|---|---|
| 启动子: | CMV |
| 克隆方法: | 多克隆位点，限制性内切酶 |
| 载体大小: | 6470 bp (查看载体序列) |
| 5' 测序引物: | Luc-F, M13-F20 |
| 载体抗性: | Ampicillin (氨苄青霉素) |
| 筛选标记: | Puromycin (嘌呤霉素) |
订购信息
| 产品编号 | 产品名称 | 规格 | 价格 |
|---|---|---|---|
| XY1399 | pMIR-REPORT Luciferase | 5ug质粒 | ¥1000.00 |
质粒图谱
载体描述
The Ambion® pMIR-REPORT™ miRNA Expression Reporter Vector System is for the measurement of miRNA expression in cells. It contains two mammalian expression vectors—one for cloning miRNA targets and evaluating miRNA regulation, and the other for the normalization of transfection efficiency.
- Clone miRNA targets and evaluate miRNA regulation
- Screen putative miRNA target sequences
- Includes both reporter and control vectors
The pMIR-REPORT™ miRNA Expression Reporter Vector System provides accurate, quantitative, in-cell measurement of miRNA expression. This validated reporter system contains two mammalian expression vectors. The pMIR-REPORT™ Luciferase miRNA Expression Reporter Vector contains firefly luciferase under the control of a mammalian promoter/terminator system, with an miRNA target cloning region downstream of the luciferase translation sequence. This vector is optimized for cloning miRNA targets and evaluating miRNA regulation. A second vector, pMIR-REPORT™ Beta-galactosidase Reporter Control Vector, is provided for normalizing transfection efficiency.
载体应用
pMIR-REPORT™ Luciferase is designed for cloning and testing putative miRNA binding sites. pMIR-REPORT™ Luciferase can be transfected into mammalian cells to evaluate endogenous miRNA expression, or used to evaluate the up- or down-regulation resulting from the transfection of Pre-miR™ miRNA Molecules or Anti-miR™ miRNA Inhibitor Molecules, respectively.
